FDA warned Synaptent, LLC over website claims that make its supplement products unapproved new drugs and misbranded.
What happened
FDA reviewed www.liftmode.com from August to October 2021 and found the company took orders there for Phenibut FAA, Phenibut HCl, and other listed products. FDA said website claims showed the products were intended to cure, mitigate, treat, or prevent disease or affect body structure or function, making them unapproved new drugs. FDA also said some products were misbranded because they lacked adequate directions or complete serving-size and net-quantity labeling.
What FDA found
Website claims stated the products were intended to treat or prevent disease or affect body structure or function, so they are drugs.
Section 201(g)(1) of the Act [21 U.S.C. §321(g)(1)]The products are not generally recognized as safe and effective for those uses and were sold without FDA approval as new drugs.
Sections 201(p), 301(d), and 505(a) [21 U.S.C. §321(p), §331(d), §355(a)]Berberine HCL, Magnolia Bark Extract, Tongkat Ali Extract, Tribulus Terrestris Extract, and Garlic Extract lacked adequate directions for use because their intended uses require a licensed practitioner.
Section 502(f)(1) [21 U.S.C. §352(f)(1)]; 21 CFR 201.5Baicalin, Curcumin, DHM, and Milk Thistle Extract did not declare a complete serving size in common household measures followed by metric quantity.
Section 403(q)(1)(A) [21 U.S.C. §343(q)(1)(A)]; 21 CFR 101.9(b)Baicalin, Curcumin, DHM, and Milk Thistle Extract labels did not express net quantity in pounds and ounces as required.
21 CFR 101.7(b)(1) and 101.7(j)(1)
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the steps taken to address the violations and prevent recurrence, with supporting documents. If corrective actions cannot be completed in that time, the company must state why and when it will finish; if it disputes the violations, it must provide reasoning and support.
Who should pay attention
- online supplement retailers selling nootropic or botanical products
- brands that rely on website disease claims for supplement marketing
- compliance teams reviewing dietary supplement labeling and claims
This is a summary. Read the original letter on fda.gov.